🇺🇸 FDA
Pipeline program

Placebo to MK-6194, MK-6194

MK-6194-007

Phase 2 small_molecule active

Quick answer

Placebo to MK-6194, MK-6194 for Non segmental vitiligo is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Non segmental vitiligo
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials